IQVIA Response to FDA Statement
May 16 2018 - 2:57PM
Business Wire
IQVIA™ (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and contract research services to
the life sciences industry. We also provide a select set of
services to the FDA and other government agencies. Recently, we
made a correction to a kilogram conversion measurement in the
United States IQVIA National Sales Perspective (NSP) market
research service affecting reported measurements for transdermal
patches in the opioid market. This kilogram measurement is reported
in the NSP market research service. This measurement conversion
issue does not impact our widely used US and global dollar and unit
information in NSP or information in any other IQVIA market
research services, methodologies or offerings.
IQVIA’s internal processes had already identified the
measurement conversion issue prior to the FDA’s notification. We
notified our clients about this measurement conversion issue in
April of this year. Ongoing steps have been undertaken to correct
this measurement conversion issue in this offering.
We stand behind our data methodologies. We value our
long-standing relationship with the FDA. We take the FDA’s concerns
seriously and will continue working with the FDA to resolve these
concerns to its satisfaction.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation, and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting
individual patient privacy. The company uses a wide variety of
privacy-enhancing technologies and safeguards to protect individual
privacy while generating and analyzing the information that helps
customers drive human health outcomes forward. IQVIA’s insights and
execution capabilities help biotech, medical device and
pharmaceutical companies, medical researchers, government agencies,
payers and other healthcare stakeholders tap into a deeper
understanding of diseases, human behaviors and scientific advances,
in an effort to advance their path toward cures. To learn more,
visit www.IQVIA.com.
Click here to subscribe to Mobile Alerts for
IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180516006324/en/
IQVIA Media RelationsTor Constantino,
+1-484-567-6732tor.constantino@iqvia.comorIQVIA Investor
RelationsAndrew Markwick,
+1-973-257-7144andrew.markwick@iqvia.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024